Opus Genetics, Inc. (IRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $384.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Opus Genetics, Inc. (IRD) Stock Forecast
Analysts expect Opus Genetics (IRD) to earn -$1.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $13.37M. Of 18 analysts, 18 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 16.7% |
| Buy | 15 | 83.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 7.2%.
- Fiscal year ending Dec 31, 2026
- -$1.28
- EPS consensus, revenue $13.37M
- Fiscal year ending Dec 31, 2027
- -$0.75
- EPS consensus, revenue $12.41M
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.28 | -$1.41 to -$1.16 | 5 | $13.37M | $5.20M to $24.50M | 13 |
| Dec 31, 2027 | -$0.75 | -$1.24 to -$0.51 | 12 | $12.41M | N/A | 18 |
Quarterly Estimates
The EPS consensus falls from -$0.09 for the quarter ending Dec 31, 2026 to -$0.16 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.19 to $0.20 | 19 | $7.64M | N/A | 18 |
| Mar 31, 2027 | -$0.16 | -$0.19 to -$0.14 | 3 | $1.41M | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.92.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.28 | -$0.94 | -$0.94 | -$0.94 | -$0.92 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.75 | -$0.72 | -$0.72 | -$0.72 | -$0.71 | N/A |
| Quarter ending Mar 31, 2027 | -$0.16 | -$0.15 | -$0.15 | -$0.15 | -$0.17 | N/A |
Frequently Asked Questions About IRD
What is the IRD stock forecast?
Consensus analyst estimates put Opus Genetics's EPS at -$1.28 for the fiscal year ending Dec 31, 2026, on revenue of $13.37M. The consensus rating from 18 analysts is Buy.
How do analysts rate IRD stock?
Of 18 analysts covering Opus Genetics, 3 rate it Strong Buy, 15 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IRD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.28, with estimates from -$1.41 to -$1.16 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.75, with estimates from -$1.24 to -$0.51 from 12 analysts.
What revenue do analysts expect from Opus Genetics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $13.37M, with estimates from $5.20M to $24.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $12.41M.
How many analysts cover IRD?
18 analysts rate Opus Genetics stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IRD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors